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1ABSTRACT
An important application of microarray technology is to relate gene expression pro¯les to var-
ious clinical phenotypes of patients. Success has been demonstrated in molecular classi¯cation
of cancer in which the gene expression data serve as predictors and di®erent types of cancer
serve as a categorical outcome variable. However, there has been less research in linking gene
expression pro¯les to the censored survival data such as patients' overall survival time or time
to cancer relapse. Due to large variability in time to certain clinical event among patients,
studying possibly censored survival phenotypes can be more informative than treating the
phenotypes as categorical variables. We propose to use the L1 penalized estimation for the
Cox model to select genes that are relevant to patients' survival and to build a predictive
model for future prediction. The computational di±culty associated with the estimation in
the high-dimensional and low-sample size settings can be e±ciently solved by using the latest
developed least angle regression method. Results from our simulation studies and applica-
tion to real data set on predicting survival after chemotherapy for patients with di®use large
B-cell lymphoma demonstrate that the proposed procedure, which we call the LARS-Lasso
procedure, can be used for identifying important genes that are related to time to death due
to cancer and for building a parsimonious model for predicting the survival of future patients.
The LARS-Lasso regression gives much better predictive performance than the L2 penalized
regression or dimension-reduction based methods such as the partial Cox regression method.
Keywords: penalized estimation, least angle regression, microarray gene expression, censored
survival data, Lasso.
2INTRODUCTION
DNA microarray technology permits simultaneous measurements of expression levels for thou-
sands of genes, which o®ers the possibility of a powerful, genome-wide approach to the genetic
basis of di®erent types of tumors. The genome-wide expression pro¯les can be used for molec-
ular classi¯cation of cancers, for studying varying levels of drug responses in the area of
pharmacogenomics and for predicting di®erent patients' clinical outcomes. The problem of
cancer class prediction using the gene expression data, which can be formulated as predicting
binary or multi-category outcomes, has been studied extensively and has been demonstrated
great promise in recent years (Alon et al., 1999; Golub et al., 199; Alizadeh et al., 2000;
Garber et al., 2001; Sorlie et al., 2001). However, there has been less development in relating
gene expression pro¯les to other phenotypes, such as quantitative continuous phenotypes or
censored survival phenotypes such as time to cancer recurrence or time to death. Due to large
variability in time to certain clinical event such as cancer recurrence among cancer patients,
studying possibly censored survival phenotypes can be more informative than treating the
phenotypes as binary or categorical variables.
The Cox regression model (Cox, 1972) is the most popular method in regression analysis
for censored survival data. However, due to the very high dimensional space of the predic-
tors, i.e., the genes with expression levels measured by microarray experiments, the standard
maximum Cox partial likelihood method cannot be applied directly to obtain the parameter
estimates. Besides the high-dimensionality, the genes expression levels of some genes are often
highly correlated, which creates the problem of high co-linearity. To deal with the problem
of collinearity, the most popular approach is to use the penalized partial likelihood, includ-
ing both the L2 penalized estimation, which is often called the ridge regression, and the L1
penalized estimation, which was proposed by Tibshirani (1995) and is called the least abso-
lute shrinkage and selection operator (Lasso) estimation. Such Lasso procedure minimizes
the negative log partial likelihood subject to the sum of the absolute value of the coe±cients
being less than a constant, s. Comparing to the L2 penalized procedure with constraints on
the sum of the square of the coe±cients, the Lasso procedure provides method for variable
selection. These penalized procedures have been investigated mainly in the setting where the
sample size is greater than the number of predictors. Li and Luan (2003) was the ¯rst to
investigate the L2 penalized estimation of the Cox model in the high-dimensional low-sample
size settings and applied their method to relate the gene expression pro¯le to survival data.
To avoid the inversion of large matrix, they used the kernel tricks to reduce the computation
3to involving only inversion of matrix of the size of the sample size. They demonstrated that
the such procedure can be applied to build a predictive model for predicting the patients's
future survival times.
One limitation of the L2 penalized estimation of the Cox model as presented in Li and Luan
(2003) is that it uses all the genes in the prediction and does not provide a way of selecting
relevant genes for prediction. However, from biological point of view, one should expect that
only a small subset of the genes is relevant to predicting the phenotypes. Including all the
genes in the predictive model introduces noises and is expected to lead to poor predictive
performance. Due to the high-dimensionality, the standard variable selection methods such
as stepwise and backward selection cannot be applied. Tibshirani (1997) further extended the
Lasso procedure for variable selection for the Cox proportional hazard models and proposed to
use the quadratic programming procedure for maximizing the L1 penalized partial likelihood
in order to obtain the parameter estimates. However, such quadratic programming procedure
cannot be applied directly to the settings when the sample size is much smaller than the
number of potential predictors, such as in the setting of microarray data analysis.
Recently, Efron et al. (2004) proposed the least angle regression (LARS) procedure for
variable selection in the linear regression setting. The LARS selects predictor by its current
correlation or angle with the response, where the current correlation is de¯ned correlation
between the predictor and the current residuals. If the active set is de¯ned as the set of
indices corresponding to covariates with the greatest absolute current correlations, as the
constraint constant s increases, the predictors are chosen one by one without deletion into
the active set. The special feature of LARS is that before a new predictor is chosen to the
active set as s increases, the corresponding increment of the coe±cients only depends on all
predictors in the active set. Efron et al. (2004) further pointed out the link between LARS and
Lasso, showing that LARS can be modi¯ed to provide solution for Lasso. Instead of solving
Lasso discretely by quadratic programming, modi¯ed LARS can give the whole solution path
of all predictors. With this powerful algorithm, Lasso can be extended to perform subset
selection in the high-dimension and low-sample settings. We propose in this paper to use
LARS algorithm to obtain the solutions for the Cox model with L1 penalty in the setting of
very high dimensional covariates such as the gene expression data obtained by microarrays.
We call such estimation procedure the LARS-Lasso procedure.
The rest of the paper is organized as follows. We ¯rst present the model and brie°y review
the Lasso estimation of the regression coe±cients and present a modi¯ed LARS procedure for
the Lasso estimation. We then evaluate the LARS-Lasso procedure by simulation studies and
4applications to real data set of di®use large B-cell lymphoma (DLBCL) survival times and
gene expression data (Rosenwald et al., 2002). Comparisons of results with methods proposed
previously by using simulations and analysis of real data set of patients with DLBCL are also
presented. Finally, we give a brief discussion of the methods and conclusions.
STATISTICAL MODELS AND METHODS
Cox proportional hazards model and Lasso estimation
Suppose that we have a sample size of n from which to estimate the relationship between
the survival time and the gene expression levels X1;¢¢¢ ;Xp of p genes. Due to censoring, for
i = 1;¢¢¢ ;n, the ith datum in the sample is denoted by (ti;±i;xi1;xi2;¢¢¢ ;xip), where ±i is
the censoring indicator and ti is the survival time if ±i = 1 or censoring time if ±i = 0, and
xi = fxi1;xi2;¢¢¢ ;xipg
0 is the vector of the gene expression level of p genes for the ith sample.
Our aim is to build the following Cox regression model for the hazard of cancer recurrence or
death at time t
¸(t) = ¸0(t)exp(¯1X1 + ¯2X2 + ¢¢¢ + ¯pXp)
= ¸0(t)exp(¯
0
X); (1)
where ¸0(t) is an unspeci¯ed baseline hazard function, ¯ = f¯1;¢¢¢ ;¯pg is the vector of the
regression coe±cients, and X = fX1;¢¢¢ ;Xpg is the vector of gene expression levels with the
corresponding sample values of xi = fxi1;¢¢¢ ;xipg for the ith sample. We de¯ne f(X) = ¯
0X
to be the linear risk score function.
Based on the available sample data, the Cox's partial likelihood (Cox, 1972) can be written
as
L(¯) =
Y
r2D
exp(¯
0xr)
P
j2Rr exp(¯
0xj)
;
where D is the set of indices of the events (e.g., deaths) and Rr denotes the set of indices
of the individuals at risk at time tr ¡ 0. Let l(¯) = logL(¯), then the Lasso estimate of ¯
(Tibshirani, 1995, 1997) can be expressed as
^ ¯(s) = argmax l(¯);subject to
p X
j=1
j¯jj · s;
where s is a tuning parameter determining how many covariates with coe±cients being zero.
Tibshirani (1997) proposed the following iterative procedure to reformulate this optimiza-
tion problem with constraint as a Lasso problem for linear regression models. Speci¯cally, let
5´ = ¯
0X, ¹ = @l=@´, A = ¡@2l=@´´T and z = ´ +A¡¹. Here since the sum of all elements in
each row (or column) of the matrix A is 0, A is clearly a singular matrix. We can however use
the generalized inverse. Alternatively, Tibshirani proposed to replace the information matrix
A with a diagonal matrix D, which has the same diagonal elements as A. However, in most of
applications, n is usually small and calculation of the generalized inverse is computationally
feasible. In addition, due the high-dimensionality of the predictors, it is important to make
the algorithm as accurate as possible. With this reparameterization, a one-term Taylor series
expansion for l(¯) has the form of
(z ¡ ´)
TA(z ¡ ´):
Although there are multiple choices of A¡, it is easy to show that if rank(A) = n ¡ 1,
for any A¡ that satis¯es AA¡A = A and z = ´ + A¡¹, (z ¡ ´)TA(z ¡ ´) is invariant to the
choice of the generalized inverse of A. To show this, let Ci = fk : i 2 Rkg denote the risk sets
containing individuals i, and Cii
0 = fk : i;i
0 2 Rkg denote the risk sets containing individuals
i and i
0. De¯ne
B =
0
B
B
B
B
B
@
1 0 ¢¢¢ 0
0 1 ¢¢¢ 0
. . .
. . . ... . . .
1 1 ¢¢¢ 1
1
C
C
C
C
C
A
;
then it is easy to verify that BAB
0 =
0
@ A(n¡1)£(n¡1) 0
0 0
1
A and (B¹)
0 = (¹1;¢¢¢ ;¹n¡1;0). If
rank(A) = n ¡ 1, then A¡ = B
0CB, where
C =
0
@ A
¡1
(n¡1)£(n¡1) ¤
¤ ¤
1
A;
and * is used to represent any values. Therefore,
(z ¡ ´)
TA(z ¡ ´) = ¹
0
A
¡¹ = (B¹)
0
CB¹ = ¹
0
¡nA
¡1
(n¡1)£(n¡1)¹¡n;
where ¹
0
¡n = (¹1;¢¢¢ ;¹n¡1):
The iterative procedure of Tibshirani (1997) involves the following four steps,
1. Fix s and initialize ^ ¯ = 0.
2. Compute ´;¹;A and z based on the current value of ^ ¯.
3. Minimize (z ¡ ¯
0X)TA(z ¡ ¯
0X) subject to
P
j¯jj · s.
64. Repeat step 2 and 3 until ^ ¯ does not change.
Tibshrani (1997) proposed to use the quadratic programming for solving Step 3. However, in
the high-dimension and low-sample size setting, i.e., in the case when p >> n, the quadratic
programming algorithm cannot be directly applied. We propose in the next section a simple
modi¯cation of the LARS algorithm of Efron et al. (2004) for Step 3.
LARS-Lasso procedure: a modi¯cation of LARS for solving Lasso
The LARS algorithm (Efron et al., 2004) is a new model selection algorithm developed for
linear regression model. The algorithm is a less greedy version of traditional forward selection
methods. One of the main advantages of LARS is its computational e±ciency. Efron et al.
(2004) also provided a simple modi¯cation of the LARS in order to obtain all Lasso solutions.
We propose to apply a modi¯ed LARS algorithm for solving Step 3 of the iterative procedure
presented in last section. First, we apply the Choleski decomposition to obtain T = A1=2 such
that T
0T = A, then Step 3 of the iterative procedure presented in the previous section can be
rewritten as
Step 3: minimize (y ¡ ¯
0 ^ X)T(y ¡ ¯
0 ^ X) subject to
P
j¯jj · s,
where y = Tz and ^ X = TX. The original LARS procedure requires pre-processing data
by centering the response to have mean 0 and standardizing the covariates to have mean
0 and unit length. By standardizing the covariates, the LARS algorithm can be performed
based only on correlation calculations. However, the algorithm still works when the predictors
are not scaled. In this case, we can modify the original correlation-based LARS procedure to
select those variables having the largest absolute inner product between the predictor ^ X and
the current residuals of y (we call the current inner product for the rest of the paper) instead
of the largest absolute current correlation, where the current residual is de¯ned as y ¡ ¯
0 ^ X
evaluated at the current estimate of ¯. We call the combined procedure the LARS-Lasso
procedure, which is computationally thrifty.
To determine the value of the tuning parameter s or the number of genes to be used in the
¯nal model, one can choose s which minimizes the cross-validated partial likelihood (CVPL)
(Verwij and Van Houwelingen, 1993; Huang and Harrington, 2002), which is de¯ned as
CV PL(s) = ¡
1
n
n X
i=1
h
l( ^ f
(¡i)(s)) ¡ l
(¡i)( ^ f
(¡i)(s))
i
;
7where ^ f(¡i)(s) is the estimate of the score function based on the LARS-Lasso procedure with
tuning parameter s from the data without the ith subject. The terms l(f) and l(¡i)(f) are
the log partial likelihoods with all the subjects and without the ith subject, respectively.
The optimal value of s is chosen to maximize the sum of the contributions of each subject
to the log partial likelihood. This CVPL is a special case of a more general cross-validated
likelihood approach for model selections (Smyth, 2001; Van Der Laan et al., 2003) and has
been demonstrated to perform well in prediction in the context of the penalized Cox regression
(Huang and Harrington, 2002).
Evaluation of the predictive performance: the time dependent ROC curves and
area under the curves
In order to assess how well the model predicts the outcome, we propose to employ the idea
of time dependent receiver-operator characteristics (ROC) curve for censored data and area
under the curve (AUC) as our criteria. These methods were recently developed by Heagerty
et al. (2000) in the context of the medical diagnosis. For a given score function f(X), we can
de¯ne time dependent sensitivity and speci¯city functions as
sensitivity(c;tjf(X)) = Prff(X) > cj±(t) = 1g;
speci¯city(c;tjf(X)) = Prff(X) · cj±(t) = 0g;
and de¯ne the corresponding ROC(tjf(X)) curve for any time t as the plot of sensitivity(c;tjf(X))
vs 1 ¡ speci¯city(c;tjf(X)) with cuto® point c varying, and the AUC as the area under the
ROC(tjf(X)) curve, denoted by AUC(tjf(X)). Here ±(t) is the event indicator at time t. A
nearest neighbor estimator for the bivariate distribution function is used for estimating these
conditional probabilities accounting for possible censoring (Akritas, 1994). Note that larger
AUC at time t based on a score function f(X) indicates better predictability of time to event
at time t as measured by sensitivity and speci¯city evaluated at time t. In our application
presented in the next section, we study several di®erent methods of constructing the score
function f(X) in the Cox model (1) and compare their predictive performance based on the
AUCs.
8EVALUATION OF THE METHODS BY SIMULATION
STUDIES
We performed simulation studies to evaluate how well the LARS-Lasso procedure performs
in the high-dimensional and low-sample size settings. We focus on whether the important
covariates that are related to survival endpoints can be selected by the LARS-Lasso procedure
and how well the model can be used for predicting the survival time for future patients.
In our simulation studies, we assume that 20 out of a total of 500 genes are related to
time to cancer recurrence through a Cox regression model with 10 coe±cients generated from
an uniform U(-1,-0.1) distribution and 10 coe±cients generated from an uniform U(0.1,1)
distribution (see ¯rst column of Table 1 for the coe±cients generated). A Weibull distribution
with the shape parameter of 5 and the scale parameter of 2 is used for the baseline hazard
function, and a uniform U(2,10) is used for simulating the censoring times. Based on this
setting, we would expect about 40% censoring.
In order to generate gene expression data for 500 predictors (genes), we ¯rst generate an
100 £ 500 dataset X from an uniform U(-1.5, 1.5) distribution. We assume that the ¯rst
20 genes with expression levels X1;X2;¢¢¢ ;X20 are related to patient's risk cancer recurrence
through a Cox model. In order to generate gene expression data for the rest of 480 genes which
are not related to the survival, we ¯rst use Gram-Schmidt orthonormalization to construct
its normalized orthogonal basis f®1;¢¢¢ ;®20;¯1;¢¢¢ ;¯80g, where ® = f®1;®2;¢¢¢ ;®20g is an
orthogonal basis of the linear space A expanded by X1;X2;¢¢¢ ;X20 and ¯ = f¯1;¯2;¢¢¢ ;¯80g
is a set of orthogonal basis of B, which is the orthogonal complement space of A. By Cauchy's
inequality, it is easy to show that if f®1;¢¢¢ ;®20;¯1;¢¢¢ ;¯80g is a set of normalized orthogonal
basis, then for any 20 £ 80 matrix T, we have corr(®y;(¯ + ®T)x) · ¸=
p
1 + ¸2, for 8x 2
R80;y 2 R20, where ¸2 is the largest eigenvalue of T
0T. Based on this result, we can generate
the expression levels of genes which are unrelated to survival from the linear space C =
f¯ + ®Tg with appropriate choice of the maximum eigenvalue of T
0T in order to control the
maximum correlation between vectors in space A and C. We considered the maximum possible
correlation of 0, 0.71, 0.82 and 0.87 in our simulations.
E®ects of between-gene correlation on identifying relevant genes
For each chosen maximum possible correlation between the relevant genes and non-relevant
genes, we generated 100 data sets of sample size of 100 individuals. For each replication,
9we applied the LARS-Lasso procedure to build a model which includes 20 genes by selecting
an appropriate s value in the LARS-Lasso estimation. Table 1 summarizes the frequencies
that the 20 relevant genes are among the ¯rst 20 genes that are selected by the LARS-Lasso
procedure. We observe the following interesting results. First, as expected, the predictors with
larger coe±cients are more likely to be selected by the LARS-Lasso procedure. Second, it is
interesting to observe that when the maximum possible correlation between the relevant and
non-relevant genes increases, i.e., when the linear space spanned by the non-relevant genes gets
close to the linear space expanded by those relevant genes, the chance of the relevant genes
with smaller coe±cients being selected gets smaller. This is because that at each step, the
LARS-Lasso procedure only selects the gene with the largest absolute current inner product
in the model. Of course, the chance of these relevant genes being selected also depends on the
sample size. For example, for the maximum possible correlation of 0.85, more relevant genes
are selected if the sample size is increased to 200 (see the last column of Table 1).
Predictive performance and comparison with other methods
We then examined the predictive performance of the proposed method. We simulated a sample
size of 100 patients as the training data set to build the predictive model and evaluated the
predictive performance based on another new data set of 100 patients (test data set). For
each simulation, we generated 500 gene expression levels for each patients with the maximum
possible between-gene correlation of 0.82. For each replication, we built a predictive model
based on the training set. We applied the CVPL to choose the tuning parameter s used in
the model. As an example, Figure 1 (a) shows the CVPL plot for one simulated data set,
indicating that the tuning parameter of s = 9 gives the best predictive performance using the
CVPL criteria, which corresponds to 38 genes. We then predicted the risk scores for the 100
patients in the test set. We repeated this procedure 100 times. We used the time-dependent
AUC as a criteria to assess the predictive performance.
Figure 1 (b) shows the average of the estimated AUCs (+/-SE) over 100 replications using
the predictive scores for the test sets, indicating a very good predictive performance. The
AUC is over 75% at the beginning of the following-ups and remains high at later time. As
a comparison, Figure 1 (c) and (d) show the AUCs plots for the predicted scores based on
the L2 penalized procedure proposed by Li and Luan (2003) and the principal-components
based partial Cox regression (PC-PCR) procedure proposed by Li and Gui (2004). Note that
both the L2 penalized procedure and the PC-PCR procedure use all the genes in building
10Table 1: Simulation results based on 100 replications. The ¯rst column shows the true coe±-
cients of the 20 genes which are related to the risk of cancer recurrence. Columns 2-5 shows
the frequency of each of these 20 relevant genes being selected by the LARS-Lasso procedure
under four di®erent correlation structures. The sample sizes are 100 patients for all the sim-
ulations. For the maximum possible correlation of 0:87, sample size of 200 patients was also
considered and the results are presented in the last column.
Maximum Correlation
0 0:71 0:82 0:87
Coe±cient 100 100 100 100 200
¯1 = 0:19 50 15 3 0 3
¯2 = 0:95 100 100 92 75 91
¯3 = 0:96 100 100 95 80 94
¯4 = 0:91 100 99 87 71 92
¯5 = 0:19 53 15 2 0 7
¯6 = 0:25 60 23 2 0 5
¯7 = 0:69 100 95 67 45 56
¯8 = 0:33 88 42 6 4 13
¯9 = 0:34 88 50 16 6 2
¯10 = 0:33 91 53 13 1 4
¯11 = ¡0:92 100 100 92 61 84
¯12 = ¡0:16 40 7 5 1 0
¯13 = ¡0:83 100 98 86 59 84
¯14 = ¡0:62 100 91 58 26 44
¯15 = ¡0:65 100 96 60 32 46
¯16 = ¡0:47 98 76 38 11 22
¯17 = ¡0:72 100 95 70 39 62
¯18 = ¡0:24 66 19 6 5 8
¯19 = ¡0:41 100 68 24 5 14
¯20 = ¡0:23 64 23 3 4 4
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Figure 1: Results of simulations. (a) CVPL plot for one simulated data set; (b) AUCs for
the test samples based on LARS-Lasso procedure; (c) AUCS for the test samples based on L2
penalized estimation; (d) AUCS for the test samples based on the PC-PCR procedure. For
each plot of (b) to (d), the three lines are the average AUCs over 100 replications together
with +/- 1SE.
12the predictive models. Clearly, neither of these procedures performed as well as the LARS-
Lasso procedure in predicting the survival times for future patients as measure by the AUCs.
We also performed L2 procedure and the PC-PCR procedure using genes selected based on
univariate Cox regression analysis and did not observe any improvement in their predictive
performances.
As another way of comparing these three di®erent methods, for each replication, we divided
the patients in the test set into high and low-risk groups based on having positive or negative
predictive risk scores and tested the statistical signi¯cance in the risk of cancer recurrence
between the two groups. We observed that for a p-value of less than 10¡5, all 100 replications
showed signi¯cant di®erence in risk between the high and low risk groups de¯ned by the
LARS-Lasso predicted scores, as compared to only 38 and 22 replications showing signi¯cant
di®erence in risk between the high and low risk groups de¯ned by the risk scores predicted by
the L2 penalized procedure and the PC-PCR procedure.
In summary, results from our simulation studies indicate that the LARS-Lasso procedure
can indeed select genes that are related to censored phenotypes, especially those genes with
relatively strong e®ects, although genes with smaller e®ects on survival are di±cult to iden-
tify, especially when the correlations between the gene expression levels are high. When the
correlations between the gene expression levels of the relevant genes and non-relevant genes
are high, the CVPL procedure tends to select more genes in building the predictive models.
However, we observed much better predictive performance of the LARS-Lasso procedure than
the procedures proposed previously (Li and Luan, 2003; Li and Gui, 2004).
APPLICATION TO PREDICTION OF SURVIVAL TIME
OF PATIENTS WITH DLBCL
To further demonstrate the utility of the LARS-Lasso procedure in relating microarray gene
expression data to censored survival phenotypes, we re-analyzed a recently published data set
of DLBCL by Rosenwald et al. (2002). This data set includes a total of 240 patients with
DLBCL, including 138 patient deaths during the followups with median death time of 2.8
years. Rosenwald et al. divided the 240 patients into a training set of 160 patients and a
validation set or test set of 80 patients and built a multivariate Cox model. The variables
in the Cox model included the average gene expression levels of smaller sets of genes in four
di®erent gene expression signatures together with the gene expression level of BMP6. It should
13be noted that in order to select the gene expression signatures, they performed a hierarchical
clustering analysis for genes across all the samples (including both test and training samples).
In order to compare our results with those in Rosenwald et al. (2002), we used the same
training and test data sets in our analysis.
The gene expression measurements of 7,399 genes are available for analysis. However,
there are a large number of missing gene expression values in the data set. Among the 7,399
genes, only 434 genes have no missing values. We ¯rst applied a nearest neighbor technique
(Troyanskaya et al., 2001) to estimate those missing values. Speci¯cally, for each gene, we ¯rst
identi¯ed 8 genes which are the nearest neighbors according to Euclidean distance. We then
¯lled the missing with the average of the nearest neighbors. Our method is slightly di®erent
from that of Troyanskaya et al. (2001) in that the nearest neighbors are not restricted to those
434 genes with no missing data. We also tried the method of Troyanskaya et al. (2001) for
¯lling the missing value, and the results of survival time prediction with two methods were
very close.
Selection of genes related to risk of death
Although the LARS-Lasso procedure can in principle be used to ¯t the Cox model with
n ¡ 1 = 159 genes based on training sample of 160 patients, the algorithm becomes unstable
when the number of variables is close to the sample size. As it was pointed out by Osborne
et al. (1998), as s increases, when the number of nonzero coe±cients are getting close to the
number of observations, Lasso may not have an unique solution. In the following analysis,
we only consider the Cox model with fewer than 100 genes. Figure 2 shows the path of the
coe±cients of the ¯rst 100 genes selected by the LARS-Lasso procedure as s =
P7399
i=1 j¯ij
increases. Note that we only obtained coe±cients at the turning points, where there is a
change (addition or deletion) in the set of genes selected in the LARS iterations. In this ¯gure,
we add lines between those points to get an approximate of the full coe±cient path. Note
that genes are chosen in order of their relevances in predicting survival. These genes would
provide a good list of candidate genes for further investigation. Table 2 shows the GenBank
ID and a brief description of the ¯rst 10 genes selected. It is interesting to note that seven of
these genes belong to the three gene expression signature groups de¯ned in Rosenwald et al.
(2002). These three signature groups include Germinal-center B-cell signature, MHC class II
signature and Lymph-node signature. No genes in the proliferation signature group de¯ned
by Rosenwald et al.(2002) were selected by LARS-Lasso. Based on our search of GenBank
14Figure 2: Approximated coe±cients' path for the ¯rst 100 genes estimated by the LARS-Lasso
procedure based on the 160 lymphoma patients in the training data set. Each line corresponds
to the estimated coe±cient for a given gene as the tuning parameter s increases. For a given
s, the y-axis gives the current estimates of the coe±cients of the genes selected.
(http://www.ncbi.nlm.nih.gov/Genbank/index.html), we found that the other three genes are
also related to lymphoma or death. The gene AA76074 is COX15 homolog and mutations
in this gene produce a defect in the mitochondrial heme biosynthetic pathway, causing early-
onset fatal hypertrophic cardiomyopathy. The gene A29003 is protein coding TCL1A gene
which has been demonstrated to be a powerful oncogene and when it is over-expressed in both
B and T cells, it predominantly yields mature B cell lymphomas. Finally, the gene L19872 is
Aryl hydrocarbon receptor (AHR), which is a ligand-activated transcription factor involved in
the regulation of biological responses to planar aromatic hydrocarbons. AHR has been shown
to regulate xenobiotic-metabolizing enzymes such as cytochrome P450, which belongs to the
lymph-node signature group.
15Table 2: GenBank ID and descriptions of the top 10 genes selected by the LARS-Lasso
procedure based on the 160 patients in the training data set. As indicated are the gene ex-
pression signature groups that these genes belong to; Germ=Germinal-center B-cell signature,
MHC=MHC class II signature, Lymph=Lymph-node signature. Genes AA760674, AA729003
and L19872 do not belong to these signature groups. No description was provided for gene
LC 29222 by Rosenwald et al.(2002).
GenBank ID Signature Description
AA760674 cytochrome oxidase assembly protein (yeast)
X00452 MHC major histocompatibility complex, class II, DQ alpha 1
AA729055 MHC major histocompatibility complex, class II, DR alpha
AA714513 MHC major histocompatibility complex, class II, DR beta 5
AA729003 T-cell leukemia/lymphoma 1A
AA805575 Germ thyroxine-binding globulin precursor
AA598653 Lymph osteoblast speci¯c factor 2 (fasciclin I-like)
LC 29222 Lymph
X59812 Lymph cytochrome P450, subfamily XXVIIA polypeptide 1
L19872 hydrocarbon receptor
Evaluation of the predictive performance
We also examined how well the model built by the LARS-Lasso procedure predicts the survival
of a future patient. Using the training set of 160 patients, we built a predictive Cox model
with the LARS-Lasso procedure using the CVPL to select the optimal tuning value s. The
minimum CVPL was obtained when s = 0:28, which corresponds to selecting four genes in
the model. We also observed that the CVPL value increases by only 0.001 when the tuning
parameter s increase from 0.28 to 0.33, which corresponds to nine genes in the model. Matter
of fact, for s ranging from 0.28 to 0.33, the predictive performances of the resulting models are
very comparable. We chose the most parsimonious model with four genes. These four genes
are AA805575, LC 29222, X00452 and X59812 (see Table 2 for a description of these four
genes), belonging to three of the four signature groups de¯ned in Rosenwald et al. (2002).
We obtained the estimates of the coe±cients of these four genes using the LARS-Lasso
procedure, denoted by vector ^ ¯. The estimated coe±cients for all four genes were negative,
indicating that high expression levels of these genes reduce the risk of death among the patients
16with DLBCL. This agrees with what Rosenwald et al. (2002) has found (see Table 2 of
their paper). Based on the estimated model with four genes, we estimated the risk scores
(f(X) = ^ ¯
0X) for the 80 patients in the test data set based on their gene expression levels
of the four genes in the predictive model. Figure 3 (a) shows the time-dependent AUCs for 1
to 20 years after diagnosis based on the estimated scores for the patients in the test set. The
AUCs are between 0.66 and 0.68 in the ¯rst 10 years of followups, indicating a reasonable
predictive performance.
To further examine whether clinically relevant groups can be identi¯ed by the model, we
used zero as a cuto® point of the risk scores and divided the test patients into two groups based
on whether they have positive or negative risk scores. Figure 3 (b) shows the Kaplan-Meier
curves for the two groups of patients, showing very signi¯cant di®erence (p-value=0.0004) in
overall survival between the high risk group (36 patients) and low risk group (44 patients).
A Comparison with other methods
As a comparison, we also analyzed the lymphoma data set using two other methods, the
partial Cox regression methods in Li and Gui (2004) and the L2 penalized method using
linear kernels proposed by Li and Luan (2003). Figure 3 (c) and (d) show the survival curves
of the two groups of the patients in the test data set de¯ned by the scores estimated by the
L2 penalized method and the PRC method. We observe that the two risk groups de¯ned by
the LARS-Lasso estimated model showed more signi¯cant di®erence in risk of death than the
groups de¯ned by the other two models (p-value of 0.0004 versus 0.003). Figure 3 (a) shows
the AUCs based on the risk scores estimated by the three di®erent methods, again indicating
better predictive performance of the LARS-Lasso procedure.
DISCUSSION AND CONCLUSIONS
It is clinically relevant and very important to predict patient's time to cancer relapse or time
to death due to cancer after treatment using gene expression pro¯les of the cancerous cells
prior to the treatment. Powerful statistical methods for such prediction allow microarray
gene expression data to be used most e±ciently. In this paper, we have proposed and studied
the LARS-Lasso procedure for censored survival data in order to identify important predictive
genes for survival using microarray gene expression data. To solve the computational di±culty,
we modi¯ed the latest developed LARS procedure (Efron et al., 2004) to obtain the solutions
for the Lasso estimation of the Cox model. Since the risk of cancer recurrence or death
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Figure 3: Results of analysis of the lymphoma data set. (a): AUCs for the test samples based
on risk scores estimated by three di®erent procedures. (b)-(d): the Kaplan-Meier curves for
the high and low risk groups de¯ned by the estimated scores for the 80 patients in the test data
set. The scores are estimated based on the models estimated by the LARS-Lasso procedure
(plot (b)), L2 penalized procedure (plot (c)) and the PC-PCR procedure (plot (d)). The
number of patients in the high risk group is 36, 35 and 31, respectively.
18due to cancer may result from the interplay between many genes, methods which can utilize
data of many genes, as in the case of our proposed procedure, are expected to show better
performance in predicting risk. Our simulation studies demonstrated that the procedure can
indeed be used to identify genes which are related to censored survival outcomes and to built
a parsimonious model for predicting future patients survival. We have also demonstrated the
applicability of our methods by analyzing time to death of the di®use large B-cell lymphoma
patients and obtained satisfactory results, as evaluated by both applying the model to the
test data set and time dependent ROC curves.
While we did not compare the new procedure with all the other procedures available, we
did compared the LARS-Lasso procedure with several other previously proposed methods
in predictive performance and found that the new procedure performed better than the L2
penalized or PC-PCR procedure (Li and Luan, 2003; Li and Gui, 2004) in predicting the future
patients' survival. We would however expect that the LARS-Lasso procedure performs better
than other dimension-reduction based procedures such as the partial least squares (Nguyen
and Rocke, 2001; Park et al., 2002) or the principal components Cox regression because the
LARS-Lasso procedure automatically selects and utilizes only the relevant genes in building
the predictive model. A comprehensive comparison of di®erent methods warrants further
research. It worth mentioning that the L1 penalized regression was also demonstrated to
perform better than other procedures in the settings of microarray gene expression data and
linear models (Segal et al., 2003)
The proposed LARS-Lasso procedure has no computational or methodological limitation
in term of the number of genes that can potentially be used in the prediction of patient's
time to clinical event. The method can in principle select n ¡ 1 genes, where n is the sample
size. However, when the number of predictors is close to the sample size, there is a risk of
over-¯tting. One drawback of the LARS-Lasso procedure is that if there is a group of variables
or genes among which the pairwise correlations are very high, the LARS-Lasso tends to select
only one variable from the group and does not care which one is selected. For genes sharing the
same biological pathways, the correlations among them can be high (Zou and Hastie, 2003).
If the LARS-Lasso procedure is used mainly for selecting important and relevant genes, one
may want to include all these highly correlated genes, if one of them is selected. If the goal is
to build a model with good predictive accuracy, this problem may not be severe since simple
models are preferred for the scienti¯c insight into the relationship between survival and gene
expressions. However, we may expect more robust prediction if the average gene expression
levels of highly correlated genes are used in the model. One way to extend the LARS-Lasso
19procedure is that at each LARS variable selection step, we selected not only one single gene
with the largest absolute current inner product, but a group of such genes with similar current
inner product. An alternative is to use the elastic net penalty as recently proposed by Zou
and Hastie (2003) for the penalized estimation.
The LARS-Lasso procedure assumes the Cox proportional hazards model, which is the
most popular model for censored survival data. However, the proportional hazards assump-
tion may not hold for gene expression data or for all diseases. It is possible to develop robust
procedures under misspeci¯ed proportional hazards models along the lines of Lin and Wei
(1989). In addition, model checking techniques analogues to those of Lin et al. (1993) can be
derived. As an alternative, we can consider similar L1 penalized estimation for the acceler-
ated failure time models (Wei, 1992) or more general semi-parametric transformation models
(Cheng et al., 1995). We are currently pursuing these alternative models.
In summary, an important application of microarray technology is to relate gene expression
pro¯les to various clinical phenotypes of patients such as time to cancer recurrent or overall
survival time. The statistical model built to relate gene expression pro¯le to the censored sur-
vival time should have the property of high predictive accuracy and parsimony. The proposed
LARS-Lasso procedure in this paper can be very useful in building a parsimonious predictive
model that can be used for classifying the future patients into clinically relevant high and low
risk groups based on the gene expression pro¯le and survival times of previous patients. The
procedure can also be applied to select important genes which are related to patients' survival
outcome.
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